Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression (QUALITY)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Bipolar Depression |
Drug: Quetiapine fumarate XR Drug: Lithium carbonate |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression |
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. [ Time Frame: Baseline, 8 weeks ] [ Designated as safety issue: No ]
The change of MADRS Total Score from baseline to the end of treatment was calculated by subtracting the MADRS Total Score assessed at week 8 from the baseline one (Baseline - 8 weeks).
The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.
- Response Rate for MADRS. [ Time Frame: baseline, week 8 ] [ Designated as safety issue: No ]
Response rate defined as the percentage of patients with a ≥50% reduction from baseline in the MADRS total score to the final assessment at week 8.
The MADRS is a 10-item scale that evaluates the core symptoms and cognitive features of clinical depression. Each MADRS item is rated on a 0 to 6 scale. The MADRS Total score ranges from 0 (min) to 60 (max). Higher MADRS scores indicate higher levels of depressive symptoms.
- Hamilton Rating Scale for Depression (HAM-D) Total Score. [ Time Frame: Baseline, 8 Weeks ] [ Designated as safety issue: No ]
The mean change of HAM-D Total Score from baseline to the end of treatment was calculated by subtracting the HAM-D Total Score assessed at week 8 from the baseline one (Baseline - week 8).
HAM-D is a multiple choice questionnaire used to rate the severity of a patient's major depression. It consists of 17 different items with possible scores from 0 to 4 or 0 to 2 or 0 to 6 depending on the items. Sum the total of all seventeen items gives the HAM-D Total Score, which may range from 0 (min) to 53 (max). The higher the score, the more severe the depression.
- Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score [ Time Frame: baseline, 8 weeks ] [ Designated as safety issue: No ]
The mean change in HAM-A total score from baseline to final assessment was calculated by subtracting the HAM-A Total score assessed at week 8 from the total score assessed at the baseline (baseline - week 8).
The HAM-A is a 14-item scale that assesses anxiety symptoms of anxiety such as "anxious mood", "tension" or "fears". Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. Sum the scores from all 14 parameters gives the HAM-A Total Score which may range from 0 (min) to 56 (max).
- Change in the Clinical Global Impression Severity (CGI-S) Score. [ Time Frame: baseline, 8 weeks ] [ Designated as safety issue: No ]
The reported mean change in the CGI-S score was calculated as baseline - week 8.
CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment. A patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
- Change in Young Mania Rating Scale (YMRS) Total Score. [ Time Frame: baseline, 8 weeks ] [ Designated as safety issue: No ]
The YMRS is a rating scale to assess manic symptoms. The scale has 11 items and is based upon patient's subjective report of his or hers clinical condition over the previous 48 hours.
The mean change in YMRS Total score reported was calculated as baseline - week 8.
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
- Change in the Pittsburgh Sleep Quality Index (PSQI)Total Score. [ Time Frame: Baseline, 8 weeks ] [ Designated as safety issue: No ]
The mean change in PSQI score from baseline to final assessment at week 8 was calculated as baseline - week 8.
PSQI evaluates 7 areas of quality and pattern of sleep: sleep quality, duration getting to sleep, sleep duration, sleep adequacy, sleep disturbance, use of sleeping pill, and somnolence). Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.
- Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score. [ Time Frame: baseline, 8 weeks ] [ Designated as safety issue: No ]
The mean change in (Q-LES-Q-Short Form) Total Score from baseline to week 8 was calculated by subtracting the 8 week value from baseline value (baseline - week 8).
The Q-LES-Q-SF is a patient self assessment questionnaire consisting of 16 self-rated questions (1 being very poor - 5 very good); the first 14 will be incorporated into a total score. Higher scores indicate better quality of life.
- Change in the Sheehan Disability Scale (SDS) Total Score. [ Time Frame: baseline, 8 weeks ] [ Designated as safety issue: No ]
The mean change in the SDS Total score from baseline to week 8 (baseline- week 8).
Sheehan Disability Scale is a 5 item scale, with a visual analog scale evaluating work/school work, social life and family life ranging from 0 to a maximum score of 30. Each one of the 3 domains is rated from 0-10 (no impairment to most severe impairment) with evaluation of not at all (0), mild (1-3), moderate (4-6), marked (7-9) and extreme (10) disability. A total score will be calculated. A score of 30 indicates most severe impairment.
- Treatment Satisfaction Questionnaire (TSQ) Scores. [ Time Frame: baseline, 8 weeks ] [ Designated as safety issue: No ]
The 14-item TAQ questionnaire evaluates the patient's overall level of satisfaction with the study medication, the effectiveness, side effects and convenience of the medication.
Effectiveness, side effects, convenience and global satisfaction is rated on a scale of 0 being the worst and 100 being very effective, no side effects or very convenient or very satisfied. Overall satisfaction is rated over a score of 5 and 5 being the best overall satisfaction.
| Enrollment: | 421 |
| Study Start Date: | April 2009 |
| Study Completion Date: | March 2011 |
| Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Quetiapin fumarate XR
Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
|
Drug: Quetiapine fumarate XR
Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
Other Name: SEROQUEL XR
|
|
Experimental: Quetiapin fumarate XR+Lithium carbonate
Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
|
Drug: Quetiapine fumarate XR
Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
Other Name: SEROQUEL XR
Drug: Lithium carbonate
Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Outpatients that meet the diagnostic criteria for bipolar disorder I and bipolar disorder II with the most recent episode depressed
- The total score of the scale that's used for the evaluation of depression (HAM-D) should be ≥20
- The total score of the scale that' used for the evaluation of mania (YMRS) should be ≤12
Exclusion Criteria:
- Patients with a current DSM-IV-TR Axis I disorder other than bipolar disorder within 6 months of enrollment. Patients who pose a current serious suicidal or homicidal risk
- Use of drugs that induce or inhibit the hepatic metabolizing enzymes within 14 days before randomisation
- Patients who are unable to discontinue all psychoactive medications, including antidepressants, antipsychotics, and mood stabilizers at least 7 days prior to randomisation and consistent with the pharmacokinetics of the drug
Contacts and Locations| Argentina | |
| Research Site | |
| La Plata, Buenos Aires, Argentina | |
| Research Site | |
| Godoy Cruz, Mendoza, Argentina | |
| Research Site | |
| Caba, Argentina | |
| Research Site | |
| Mendoza, Argentina | |
| Brazil | |
| Research Site | |
| Aparecida de Goiania, GO, Brazil | |
| Research Site | |
| Sao Paulo, SP, Brazil | |
| Research Site | |
| Rio de Janeiro, Brazil | |
| Chile | |
| Research Site | |
| Santiago, Chile | |
| Colombia | |
| Research Site | |
| Medellin, Antioquia, Colombia | |
| Research Site | |
| Bogota D.c, Cundinamarca, Colombia | |
| Guatemala | |
| Research Site | |
| Guatemala, Ciudad de Guatemala, Guatemala | |
| Mexico | |
| Research Site | |
| Monterrey, Nuevo Leon, Mexico | |
| Research Site | |
| Durango, Mexico | |
| Research Site | |
| Monterrey, Mexico | |
| Research Site | |
| San Luis Potosi, Mexico | |
| Peru | |
| Research Site | |
| Lima, Peru | |
| Turkey | |
| Research Site | |
| Ankara, Turkey | |
| Research Site | |
| Elazig, Turkey | |
| Research Site | |
| Istanbul, Turkey | |
| Research Site | |
| Izmir, Turkey | |
| Research Site | |
| Kocaeli, Turkey | |
| Research Site | |
| Malatya, Turkey | |
| Research Site | |
| Manisa, Turkey | |
| Venezuela | |
| Research Site | |
| Caracas, Venezuela | |
| Principal Investigator: | Simavi Vahip, Prof. Dr. | Ege University Faculty of Medicine Psychiatry Department İzmir |
More Information
No publications provided
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00883493 History of Changes |
| Other Study ID Numbers: | D1443L00055 |
| Study First Received: | April 16, 2009 |
| Results First Received: | February 29, 2012 |
| Last Updated: | July 2, 2012 |
| Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica Brazil: National Health Surveillance Agency Chile: Instituto de Salud Publica de Chile Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos Guatemala: SUGEME (Independent Ethics Committe) y Comite de Farmacovigilancia Mexico: National Institute of Public Health, Health Secretariat Peru: General Directorate of Pharmaceuticals, Devices, and Drugs Peru: Ministry of Health Venezuela: Instituto Nacional de Higiene Turkey: Ministry of Health |
Keywords provided by AstraZeneca:
|
Acute bipolar depression Lithium carbonate quetiapine fumarate MADRS |
Additional relevant MeSH terms:
|
Bipolar Disorder Depression Depressive Disorder Affective Disorders, Psychotic Mood Disorders Mental Disorders Behavioral Symptoms Lithium Quetiapine Lithium Carbonate Antipsychotic Agents |
Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Antimanic Agents Antidepressive Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013